Jiangsu Alphamab Biopharmaceuticals, 3D Medicines (Beijing) and Glenmark announce the signing of a License Agreement for KN035 (Envafolimab) for Multiple Geographies around the World

Bengaluru : Glenmark Specialty S.A. (GSSA), a subsidiary of Glenmark Pharmaceuticals Ltd. (Glenmark), today announced the signing of a license agreement with JIANGSU ALPHAMAB BIOPHARMACEUTICALS CO., LTD (Jiangsu Alphamab) and 3D MEDICINES (BEIJING) C

Related Keywords

Russia ,China ,Bengaluru ,Karnataka ,India ,United States ,America ,Chinese ,Asia Pacific ,Jiangsu Alphamab ,Tracon Pharma ,Glenn Saldanha ,National Medical Products Administration Chinese ,Glenmark Pharmaceuticals Ltd ,Glenmark Pharmaceuticals ,Middle East ,Latin America ,Managing Director ,National Medical Products Administration ,Emerging Markets ,Undifferentiated Pleomorphic Sarcoma ,Fast Track ,Biliary Tract ,